Movement Alert｜ImmunityBio Rises 5.03% in Regular Trading, Positive Clinical Data and Patent Grants Fuel Rally

Market Focus05-21

On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments announced in recent days.

At the 2026 American Urological Association Annual Meeting, ImmunityBio presented positive efficacy comparison data showing its ANKTIVA (Nai) plus BCG therapy demonstrated favorable complete response rates compared with Nadofaragene and TAR-200 therapies. Additionally, the company received five US patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with validity extending until at least 2035. These patents protect the product, dosing regimen, commercial kit, and treatment methods for non-muscle invasive bladder cancer.

Further bolstering sentiment, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory to obtain rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, backed by Phase 3 data demonstrating non-inferiority to TICE BCG.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180096844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180096844","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Rises 5.03% in Regular Trading, Positive Clinical Data and Patent Grants Fuel Rally","media":"Market Focus","content":"<p><p>On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments announced in recent days.</p><p>At the 2026 American Urological Association Annual Meeting, ImmunityBio presented positive efficacy comparison data showing its ANKTIVA (Nai) plus BCG therapy demonstrated favorable complete response rates compared with Nadofaragene and TAR-200 therapies. Additionally, the company received five US patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with validity extending until at least 2035. These patents protect the product, dosing regimen, commercial kit, and treatment methods for non-muscle invasive bladder cancer.</p><p>Further bolstering sentiment, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory to obtain rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, backed by Phase 3 data demonstrating non-inferiority to TICE BCG.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Rises 5.03% in Regular Trading, Positive Clinical Data and Patent Grants Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Rises 5.03% in Regular Trading, Positive Clinical Data and Patent Grants Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 03:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments announced in recent days.</p><p>At the 2026 American Urological Association Annual Meeting, ImmunityBio presented positive efficacy comparison data showing its ANKTIVA (Nai) plus BCG therapy demonstrated favorable complete response rates compared with Nadofaragene and TAR-200 therapies. Additionally, the company received five US patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with validity extending until at least 2035. These patents protect the product, dosing regimen, commercial kit, and treatment methods for non-muscle invasive bladder cancer.</p><p>Further bolstering sentiment, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory to obtain rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, backed by Phase 3 data demonstrating non-inferiority to TICE BCG.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1180096844","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180096844","pubTimestamp":1779305651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"走势提示|ImmunityBio常规交易上涨5.03%，积极的临床数据和专利授权推动涨势","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments announced in recent days.At the 2026 American Urological Association Annual Meeting, ImmunityBio presented positive efficacy comparison data showing its ANKTIVA (Nai) plus BCG therapy demonstrated favorable complete response rates compared with Nadofaragene and TAR-200 therapies. Additionally, the company received five US patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with validity extending until at least 2035. These patents protect the product, dosing regimen, commercial kit, and treatment methods for non-muscle invasive bladder cancer.Further bolstering sentiment, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory to obtain rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, backed by Phase 3 data demonstrating non-inferiority to TICE BCG.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180096844","isCrawlerRequest":true}